Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]	Total
Beginning balance at Dec. 31, 2020	$ 2,537	$ 64	$ 87,570	$ (88,275)		$ (2,369)	$ (473)
Beginning balance,shares at Dec. 31, 2020	1,228,075	63,819,935
Dividends declared - Series B Convertible Preferred Stock	$ 221			(221)
Dividends declared - series B convertible preferred stock, shares	73,821
Conversions - Series B Convertible Preferred Stock	$ (406)		406
Conversions - Series B Convertible Preferred Stock, shares	(210,448)	210,448
Conversions - Senior Secured Convertible Note		$ 1	1,722				1,723
Conversions - Senior Secured Convertible Note, shares		667,668
Purchase - Employee Stock Purchase Plan			436				436
Stock-based compensation - PAVmed Inc.			4,473				4,473
Stock-based compensation - majority-owned subsidiary			111			6,045	6,156
Net Loss				(33,129)		(3,318)	(36,447)
Vest - restricted stock awards
Vest - restricted stock awards, shares		150,000
Exercise - Series Z warrants		$ 3	4,680				4,683
Exercise - Series Z warrants, shares		2,927,125
Exercise - stock options			953				953
Exercise - stock options, shares		604,500
Purchase - Employee Stock Purchase Plan, shares		234,592
Exercise - Series W warrants			20				20
Exercise - Series W warrants, shares		3,945
Issue common stock – registered offerings, net		$ 16	53,688				53,704
Issue common stock - registered offerings, net, shares		15,782,609
Ending balance at Sep. 30, 2021	$ 2,352	$ 84	154,059	(121,625)		364	35,234
Ending balance,shares at Sep. 30, 2021	1,091,448	84,400,822
Beginning balance at Dec. 31, 2020	$ 2,537	$ 64	87,570	(88,275)		(2,369)	(473)
Beginning balance,shares at Dec. 31, 2020	1,228,075	63,819,935
Ending balance at Dec. 31, 2021	$ 2,419	$ 86	198,071	(138,910)		17,752	79,418
Ending balance,shares at Dec. 31, 2021	1,113,919	86,367,845
Beginning balance at Jun. 30, 2021	$ 2,499	$ 83	149,694	(109,325)		(911)	42,040
Beginning balance,shares at Jun. 30, 2021	1,185,685	82,576,816
Dividends declared - Series B Convertible Preferred Stock	$ 73			(73)
Dividends declared - series B convertible preferred stock, shares	24,577
Conversions - Series B Convertible Preferred Stock	$ (220)		220
Conversions - Series B Convertible Preferred Stock, shares	(118,814)	118,814
Purchase - Employee Stock Purchase Plan			131				131
Stock-based compensation - PAVmed Inc.			1,218				1,218
Stock-based compensation - majority-owned subsidiary			56			2,716	2,772
Net Loss				(12,227)		(1,441)	(13,668)
Exercise - Series Z warrants		$ 1	1,897				1,898
Exercise - Series Z warrants, shares		1,186,467
Exercise - stock options			823				823
Exercise - stock options, shares		483,668
Purchase - Employee Stock Purchase Plan, shares		31,112
Exercise - Series W warrants			20				20
Exercise - Series W warrants, shares		3,945
Ending balance at Sep. 30, 2021	$ 2,352	$ 84	154,059	(121,625)		364	35,234
Ending balance,shares at Sep. 30, 2021	1,091,448	84,400,822
Beginning balance at Dec. 31, 2021	$ 2,419	$ 86	198,071	(138,910)		17,752	79,418
Beginning balance,shares at Dec. 31, 2021	1,113,919	86,367,845
Dividends declared - Series B Convertible Preferred Stock	$ 205			(205)
Dividends declared - series B convertible preferred stock, shares	68,227
Conversions - Series B Convertible Preferred Stock
Conversions - Series B Convertible Preferred Stock, shares	(45)	45
Conversions - Senior Secured Convertible Note		$ 5	10,107				10,112
Conversions - Senior Secured Convertible Note, shares		5,013,908
Exercise - stock options of majority-owned subsidiary						694	694
Purchase - Employee Stock Purchase Plan			218		140		358
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						109	109
Issuance - majority-owned subsidiary common stock - Committed Equity Facility, net of deferred financing charges						1,767	1,767
Impact of subsidiary equity transactions			1,375			(1,375)
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						427	427
Stock-based compensation - PAVmed Inc.			4,206				4,206
Stock-based compensation - majority-owned subsidiary						10,377	10,377
Treasury stock					(548)		(548)
Treasury stock, shares		(188,846)
Net Loss				(68,523)		(10,143)	(78,666)
Vest - restricted stock awards		$ 1	(1)
Vest - restricted stock awards, shares		541,666
Exercise - Series Z warrants
Exercise - Series Z warrants, shares		5
Exercise - stock options			302				302
Exercise - stock options, shares		299,999
Purchase - Employee Stock Purchase Plan, shares		194,240
Ending balance at Sep. 30, 2022	$ 2,624	$ 92	214,278	(207,638)	(408)	19,608	28,556
Ending balance,shares at Sep. 30, 2022	1,182,101	92,228,862
Beginning balance at Jun. 30, 2022	$ 2,554	$ 87	201,327	(181,442)	(548)	19,426	41,404
Beginning balance,shares at Jun. 30, 2022	1,158,950	87,023,211
Dividends declared - Series B Convertible Preferred Stock	$ 70			(70)
Dividends declared - series B convertible preferred stock, shares	23,196
Conversions - Series B Convertible Preferred Stock
Conversions - Series B Convertible Preferred Stock, shares	(45)	45
Conversions - Senior Secured Convertible Note		$ 5	10,107				10,112
Conversions - Senior Secured Convertible Note, shares		5,013,908
Exercise - stock options of majority-owned subsidiary						6	6
Purchase - Employee Stock Purchase Plan					140		140
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						109	109
Issuance - majority-owned subsidiary common stock - Committed Equity Facility, net of deferred financing charges						1,767	1,767
Impact of subsidiary equity transactions			1,363			(1,363)
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						186	186
Stock-based compensation - PAVmed Inc.			1,481				1,481
Stock-based compensation - majority-owned subsidiary						3,283	3,283
Treasury stock
Treasury stock, shares		191,698
Net Loss				(26,126)		(3,806)	(29,932)
Ending balance at Sep. 30, 2022	$ 2,624	$ 92	$ 214,278	$ (207,638)	$ (408)	$ 19,608	$ 28,556
Ending balance,shares at Sep. 30, 2022	1,182,101	92,228,862